AnalystsAlbert LoweAlbert Lowe's Stock Forecasts
AnalystsAlbert Lowe
Sectors:
Industries:
Analyst Ranking
Top 27%
#1399 out of 5290 analysts
Average Return
+48.87%
Win Rate
45%5 out of 11
Risk vs Reward
Poor
Good
Albert Lowe's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Opus Genetics IncIRD | +655.99% | $0.71 | $5.36 | 2025-04-10 - 2026-04-10 | Buy |
Neurogene IncNGNE | +49.19% | $18.42 | $27.48 | 2025-06-16 - 2026-06-04 | Buy |
Lineage Cell Therapeutics IncLCTX | +42.53% | $0.87 | $1.24 | 2024-08-19 - 2025-08-19 | Buy |
Palvella Therapeutics IncPVLA | +22.41% | $93.80 | $114.82 | 2025-12-03 - 2026-06-04 | Buy |
Cardiff Oncology IncCRDF | +2.84% | $2.11 | $2.17 | 2024-09-05 - 2025-09-05 | Buy |
Albert Lowe Analyst Color
Get additional color on Albert Lowe's coverage of popular stocks
Albert Lowe's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Cardiff Oncology IncCRDF | 2 | Hold | $2.00 | +29.03% | Downgrades | 2 days ago |
Spruce Biosciences IncSPRB | 1 | Buy | $140.00 | +163.31% | Initiates Coverage On | a month ago |
Palvella Therapeutics IncPVLA | 1 | Buy | $175.00 | +52.41% | Initiates Coverage On | 6 months ago |
Neurogene IncNGNE | 1 | Buy | $50.00 | +81.95% | Initiates Coverage On | a year ago |
Atossa Therapeutics IncATOS | 1 | Buy | $20.00 | +312.37% | Initiates Coverage On | a year ago |
Opus Genetics IncIRD | 1 | Buy | $6.00 | N/A | Initiates Coverage On | a year ago |
Skye Bioscience IncSKYE | 2 | Buy | $14.00 | N/A | Maintains | a year ago |
Sab Biotherapeutics IncSABS | 1 | Buy | $11.00 | N/A | Initiates Coverage On | 2 years ago |
Lineage Cell Therapeutics IncLCTX | 1 | Buy | $4.00 | N/A | Initiates Coverage On | 2 years ago |
Pmv Pharmaceuticals IncPMVP | 1 | Buy | $6.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.